Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Lobeglitazone in Type 2 Diabetes
NCT05915949Phase 4Unknown
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, lobeglitazone in type 2 diabetes mellitus (T2DM), sponsored by Seoul National University Bundang Hospital. Status: unknown.
02
Drugs
dapagliflozinlobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05915949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915949.